Candriam S.C.A. Prometheus Biosciences, Inc. Transaction History

Candriam S.C.A.

  • $17.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$103.46 - $126.29 $1.55 Million - $1.89 Million
15,000 Added 20.0%
90,000 $9.66 Million
Q4 2022

Feb 13, 2023
SELL
$36.06 - $117.21 $540,900 - $1.76 Million
-15,000 Reduced 16.67%
75,000 $8.25 Million
Q3 2022

Nov 10, 2022
BUY
$28.17 - $59.01 $2.54 Million - $5.31 Million
90,000 New
90,000 $5.31 Million

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email